DelveInsight’s, “Ovarian Cancer Pipeline Insight 2024” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Ovarian Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Ovarian Cancer Research. Learn more about our innovative pipeline today! @ Ovarian Cancer Pipeline Outlook
Key Takeaways from the Ovarian Cancer Pipeline Report
- In November 2024;- Dana-Farber Cancer Institute- This is an open-label, single site, phase 1b study to evaluate the safety and effectiveness of the use of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy in recurrent, high grade ovarian cancer. Participants will be enrolled to test the safety of intraperitoneal CIML NK cell therapy. The U.S. Food and Drug Administration (FDA) has not approved CIML NK cell therapy as a treatment for recurrent, high grade ovarian cancer.
- In October 2024:- Tesaro Inc.- This study aims to assess efficacy of Niraparib (GSK3985771) as maintenance treatment in participants with Stage III or IV ovarian cancer. Participants must have completed front-line platinum based regimen with complete response (CR) or partial response (PR). Data collection for Secondary Outcome measures is ongoing and the approximate duration of the study will be 7 years.
- In October 2024:- Takeda- The study will be conducted in two phases including Phase 1 Part and Phase 2 Part. In Phase 1 Part, the participants will stay in the hospital for 3 days at least after their 1st injection for some tests and to check for any side effects from their treatment. In Phase 2 Part, participants will visit their study hospital for multiple times. In both phases, the participants will receive TAK-853 on the first days of each 3-week cycle.
- In October 2024:- Theolytics Limited- A Phase I/IIa, Open-label, Dose Finding, Safety, Tolerability and Exploratory Trial of THEO-260 in Patients With High Grade Serous or Endometrioid Ovarian Cancer. The goal of this clinical trial is to establish if THEO-260 is safe to administer to adult females with ovarian cancer. It will also aim to establish if THEO-260 is able to treat ovarian cancer.
- DelveInsight’s Ovarian Cancer pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Ovarian Cancer treatment.
- The leading Ovarian Cancer Companies such as Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics and others.
- Promising Ovarian Cancer Therapies such as SAR245409, Karenitecin, Topotecan, OTL38, Magrolimab, Avelumab, and others.
Stay informed about the cutting-edge advancements in Ovarian Cancer treatments. Download for updates and be a part of the revolution in care @ Ovarian Cancer Clinical Trials Assessment
Ovarian Cancer Emerging Drugs Profile
- Atezolizumab: Genentech
Atezolizumab is a humanized kappa immunoglobulin (Ig) G1 monoclonal antibody consisting of two heavy chains (448 amino acids) and two light chains (214 amino acids) and is produced in Chinese hamster ovary cells. Atezolizumab was engineered to eliminate Fc-effector function via a single amino acid substitution (asparagine to alanine) at position 298 on the heavy chain, which results in a non-glycosylated antibody that has minimal binding to Fc receptors and, consequently, eliminates detectable Fc-effector function and depletion of cells expressing programmed death−ligand 1 (PD-L1) in humans. Atezolizumab targets human PD-L1 and inhibits its interaction with its receptors, programmed death−1 (PD-1) and B7.1, both of which can provide inhibitory signals to T cells. The drug is currently in phase 3 of clinical trials for the treatment of Ovarian Cancer.
- Tisotumab Vedotin: Genmab
Tisotumab vedotin, also known as HuMax-TF, HuMax®-TF-ADC or TF-011-MMAE, is an antibody-drug conjugate (ADC) targeted to tissue factor (TF), a protein involved in tumor signaling and angiogenesis. Tisotumab vedotin includes an antibody targeting TF conjugated with monomethyl auristatin E (MMAE) via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. The drug is currently in phase 2 of clinical trials for the treatment of Ovarian Cancer.
- SON-1010: Sonnet Biotherapeutics
SON-1010 is a proprietary version of native human IL-12, configured using Sonnet's fully human albumin binding (FHAB®) platform, which targets the tumor microenvironment (TME) and extends the pharmacokinetics (PK) and subsequent pharmacodynamics (PD) of the molecule. Sonnet and Roche have entered into a Master Clinical Trial and Supply Agreement (MCSA), along with ancillary Quality and Safety Agreements, to study the safety and efficacy of the combination of SON-1010 and atezolizumab in a platinum-resistant ovarian cancer (PROC) patient setting. Currently the drug is in the Phase I/II stage of its development for the treatment of ovarian cancer.
- DS-6000a: Daiichi Sankyo Company
DS-6000a is an antibody-drug conjugate, comprised of an humanized anti-CDH6 IgG1 monoclonal antibody attached to a topoisomerase I (TOP1) inhibitor payload via a cleavable linker. DS-6000a specifically binds to CDH6 on the surface of tumor cells and is internalized upon binding. The payload is then released, resulting in target cell apoptosis. In preclinical studies, DS-6000a inhibited tumor growth and induced tumor regression in CDH6-expressing RCC and OVC. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Ovarian Cancer.
Learn more about Ovarian Cancer Drugs opportunities in our groundbreaking Ovarian Cancer Research and development projects @ Ovarian Cancer Unmet Needs
Ovarian Cancer Companies
Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics and others.
Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Ovarian Cancer Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Discover the latest advancements in Ovarian Cancer treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Ovarian Cancer Market Drivers and Barriers, and Future Perspectives
Scope of the Ovarian Cancer Pipeline Report
- Coverage- Global
- Ovarian Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Ovarian Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Ovarian Cancer Companies- Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics and others.
- Ovarian Cancer Therapies- SAR245409, Karenitecin, Topotecan, OTL38, Magrolimab, Avelumab, and others.
For a detailed overview of our latest research findings and future plans, read the full details of Ovarian Cancer Pipeline on our website @ Ovarian Cancer Emerging Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Ovarian Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Ovarian Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Atezolizumab: Genentech
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Tisotumab Vedotin: Genmab
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- DS-6000a: Daiichi Sankyo Company
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Product Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Ovarian Cancer Key Companies
- Ovarian Cancer Key Products
- Ovarian Cancer- Unmet Needs
- Ovarian Cancer- Market Drivers and Barriers
- Ovarian Cancer- Future Perspectives and Conclusion
- Ovarian Cancer Analyst Views
- Ovarian Cancer Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
